Summit Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

SMMT$17.83-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount
Balance at December 31, 2025	775,371,200	$7,754	$2,947,805	$(2,540)		$(2,294,159)		$658,860
Issuance of common stock under stock purchase plans and exercise of stock options	646,274	6	3,791	—		—		3,797
Stock-based compensation	—	—	72,791	—		—		72,791
Net other comprehensive loss	—	—	—	(92)		—		(92)
Net loss	—	—	—	—		(189,424)		(189,424)
Balance at March 31, 2026	776,017,474	$7,760	$3,024,387	$(2,632)		$(2,483,583)		$545,932
Issuance of common stock upon exercise of stock options	670,453	7	3,658	—		—		3,665
Proceeds from at-the-market offering, net of commissions of $3,463 (2)	16,432,435	164	227,249	—		—		227,413
Stock-based compensation	—	—	68,706		—		68,706
Net other comprehensive loss	—	—	—	(33)		—		(33)
Net loss	—	—	—	—		(215,700)		(215,700)
Balance at June 30, 2026	793,120,362	$7,931	$3,324,000	$(2,665)		$(2,699,283)		$629,983
Issuance of common stock under stock purchase plans and exercise of stock options	406,901	4	2,601	—		—		2,605
Proceeds from at-the-market offering, net of commissions of $1,283	6,199,155	62	92,765	—		—		92,827
Stock-based compensation	—	—	47,686	—		—		47,686
Net other comprehensive loss	—	—	—	(33)		—		(33)
Net loss	—	—	—	—		(208,385)		(208,385)
Balance at September 30, 2026	799,726,418	$7,997	$3,467,052	$(2,698)		$(2,907,668)		$564,683

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount
Balance at December 31, 2024	737,626,004	$7,376	$1,598,230	$(2,285)	$(1,214,573)		$388,748
Issuance of common stock under stock purchase plans and exercise of stock options and warrants (2)	3,983,386	40	7,637	—	—		7,677
Stock-based compensation	—	—	11,096	—	—		11,096
Net other comprehensive loss	—	—	—	(278)		(278)
Net loss	—	—	—	—	(62,913)		(62,913)
Balance at March 31, 2025	741,609,390	$7,416	$1,616,963	$(2,563)	$(1,277,486)		$344,330
Issuance of common stock upon exercise of stock options and warrants (2)	1,197,282	12	2,210	—	—		2,222
Stock-based compensation	—	—	478,784	—	—		478,784
Net other comprehensive loss	—	—	—	(189)	—		(189)
Net loss	—	—	—	—	(565,708)		(565,708)
Balance at June 30, 2025	742,806,672	$7,428	$2,097,957	$(2,752)	$(1,843,194)		$259,439
Issuance of common stock under stock purchase plans and exercise of stock options	313,068	3	2,046	—	—		2,049
Proceeds from at-the-market offering, net of commissions and offering costs of $794	1,322,793	13	31,751	—	—		31,764
Stock-based compensation	—	—	130,761	—	—		130,761
Net other comprehensive gain	—	—	—	43	—		43
Net loss	—	—	—	—	(231,793)		(231,793)
Balance at September 30, 2025	744,442,533	$7,444	$2,262,515	$(2,709)	$(2,074,987)		$192,263

(2) Refer to Note 12 – Related Party Transactions.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.